NCT00736450View on ClinicalTrials.gov

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 23, 2008

Primary Completion Date

October 9, 2012

Study Completion Date

October 9, 2012

Conditions
Contiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaStage I Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Large Cell Lymphoma
Interventions
BIOLOGICAL

oblimersen sodium

Given IV

BIOLOGICAL

rituximab

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given orally

PROCEDURE

biopsy

Correlative studies

GENETIC

microarray analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

gene expression analysis

Correlative studies

GENETIC

cytogenetic analysis

Correlative studies

Trial Locations (2)

68803

Saint Francis Medical Center, Grand Island

68198-6805

University of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

Genta Incorporated
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genta Incorporated

INDUSTRY

lead

University of Nebraska

OTHER

NCT00736450 - Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter